LncRNA 51325 Alleviates Bone Cancer Induced Hyperalgesia Through Inhibition of Pum2
Yahui Wang,Chengfei Xu,Peng Liu,Qiuli He,Shihua Zhang,Zhihao Liu,Chaobo Ni,Liping Chen,Tong Zhi,Longsheng Xu,Liang Cheng,Xuewu Lin,Ming Yao,Huadong Ni
DOI: https://doi.org/10.2147/jpr.s446635
IF: 2.8319
2024-01-17
Journal of Pain Research
Abstract:Yahui Wang, 1, 2, &ast Chengfei Xu, 3, &ast Peng Liu, 2 Qiuli He, 1 Shihua Zhang, 1 Zhihao Liu, 1 Chaobo Ni, 1 Liping Chen, 1 Tong Zhi, 1 Longsheng Xu, 1 Liang Cheng, 3 Xuewu Lin, 2 Ming Yao, 1 Huadong Ni 1, 4 1 Department of Anesthesiology and Pain Research Center, the Affiliated Hospital of Jiaxing University, Jiaxing, 314001, People's Republic of China; 2 Department of Pain Management, the First Affiliated Hospital of Bengbu Medical College, Bengbu City, 233000, People's Republic of China; 3 Department of Anesthesiology, Bengbu Third People's Hospital, Bengbu City, 233000, People's Republic of China; 4 Institute of Neuroscience, Soochow University, Suzhou, 215123, People's Republic of China &astThese authors contributed equally to this work Correspondence: Huadong Ni; Ming Yao, Department of Anesthesiology and Pain Research center, the Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing, 314001, People's Republic of China, Email ; Background: Bone cancer pain (BCP) represents one of the most challenging comorbidities associated with cancer metastasis. Long non-coding RNAs (lncRNAs) have garnered attention as potential therapeutic agents in managing neuropathic pain. However, their role in the regulation of nociceptive information processing remains poorly understood. In this study, we observed a significant down-regulation of the spinal lncRNA ENSRNOG00000051325 (lncRNA51325) in a rat model of bone cancer pain. Our study sought to elucidate the potential involvement of lncRNA51325 in the development of BCP by modulating the expression of molecules associated with pain modulation. Methods: We established the BCP model by injecting Walker 256 cells into the tibial plateau of rats. We conducted tests on the pain behaviors and anxiety-like responses of rats through von-Frey test, Gait analysis, and Open Field Test. Spinal lumbar expansion was harvested for molecular biology experiments to explore the relationship between lncRNA51325 and Pumilio RNA binding family member 2 (Pum2). Results: Notably, the overexpression of lncRNA51325 effectively attenuated mechanical allodynia in rats afflicted with BCP, whereas the knockdown of lncRNA51325 induced pain behaviors and anxiety-like responses in naïve rats. Additionally, we observed a time-dependent increase in the expression of Pum2 in BCP-afflicted rats, and intrathecal injection of Pum2-siRNA alleviated hyperalgesia. Furthermore, our investigations revealed that lncRNA51325 exerts a negative modulatory effect on Pum2 expression. The overexpression of lncRNA51325 significantly suppressed Pum2 expression in BCP rats, while the knockdown of lncRNA51325 led to elevated Pum2 protein levels in the spinal cord of naïve rats. Subsequent treatment with Pum2-siRNA mitigated the downregulation of lncRNA51325-induced mechanical allodynia in naïve rats. Conclusion: Our findings indicate that lncRNA51325 plays a role in regulating bone cancer pain by inhibiting Pum2 expression, offering a promising avenue for novel treatments targeting nociceptive hypersensitivity induced by bone metastatic cancer. Keywords: long non-coding RNA, bone cancer pain, Pum2, spinal cord Numerous cancer types, 1 including lung, breast, prostate, thyroid, and kidney cancer, have been identified to exhibit bone metastasis in advanced stages. 2 This metastatic process can lead to adverse consequences, including fractures, 3 pain, hypercalcemia, and compression of the spinal cord and nerves. 4 Notably, bone cancer pain (BCP) is a persistent and intricate form of pain that markedly diminishes a patient's quality of life. 5 Thus, the imperative task at hand is the discovery of novel therapeutic modalities and medications aimed at enhancing the quality of life for individuals afflicted by bone cancer pain. Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts exceeding 200 nucleotides in length. 6,7 Accumulating research underscores their pivotal roles in diverse physiological and pathological phenomena, 7 including lung metastasis in breast cancer, 6 ischemic stroke, 8 cartilage differentiation in osteoarthritis, 9 peripheral neuropathies, 10 and various neuropathic pain conditions. 11–13 Pumilio protein, a member of the RNA-binding PUF family, which includes Pum1 and Pum2, 14 serves as a vital post-transcriptional regulatory factor with implications for genomic stability. 15 It has been established that lo -Abstract Truncated-
clinical neurology